Neuphoria Therapeutics Inc. Other Comprehensive Income (Loss), Tax
Neuphoria Therapeutics Inc. (NEUP) reported Other Comprehensive Income (Loss), Tax of $781.90 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossTax · last filed 2026-09-18
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for the quarter ending 2026-06-30 was $1.56M.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for the quarter ending 2026-03-31 was -$157.90K, a 180.63% decline year-over-year.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for the quarter ending 2025-12-31 was -$570.58K, a 144.28% decline year-over-year.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for the quarter ending 2025-09-30 was -$49.22K.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for fiscal 2026 was $781.90K, a 363.95% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for fiscal 2025 was $168.53K, a 272.95% increase from fiscal 2024.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for fiscal 2024 was $45.19K, a 95.64% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. other comprehensive income (loss), tax for fiscal 2023 was $1.04M.
| Period end | Other Comprehensive Income (Loss), Tax 3 month | Other Comprehensive Income (Loss), Tax 6 month | Other Comprehensive Income (Loss), Tax 9 month | Other Comprehensive Income (Loss), Tax 12 month | Other Comprehensive Income (Loss), Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.56M derived: 10-K 12 month − 3 quarters · filed 2026-09-18 | $1.40M derived: sum of 2 quarters · filed 2026-09-18 | $831.12K derived: sum of 3 quarters · filed 2026-09-18 | $781.90K 10-K · filed 2026-09-18 | |
| 2026-03-31 | -$157.90K 10-Q · filed 2026-05-15 | -$728.48K derived: sum of 2 quarters · filed 2026-05-15 | -$777.70K derived: sum of 3 quarters · filed 2026-05-15 | ||
| 2025-12-31 | -$570.58K 10-Q · filed 2026-05-15 | -$619.80K derived: sum of 2 quarters · filed 2026-05-15 | |||
| 2025-09-30 | -$49.22K 10-Q · filed 2026-05-15 | ||||
| 2025-06-30 | $168.53K 10-K · filed 2026-09-18 | ||||
| 2025-03-31 | $195.82K 10-Q · filed 2026-05-15 | $1.48M derived: sum of 2 quarters · filed 2026-05-15 | $898.87K derived: sum of 3 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $1.29M 10-Q · filed 2026-05-15 | $703.05K derived: sum of 2 quarters · filed 2026-05-15 | |||
| 2024-09-30 | -$585.38K 10-Q · filed 2026-05-15 | ||||
| 2024-06-30 | $45.19K 10-K · filed 2025-09-29 | -$45.19K 10-K · filed 2024-09-30 | |||
| 2024-03-31 | $561.95K 10-Q · filed 2025-05-20 | $110.86K derived: sum of 2 quarters · filed 2025-05-20 | $174.33K derived: sum of 3 quarters · filed 2025-05-20 | ||
| 2023-12-31 | -$451.08K 10-Q · filed 2025-05-20 | -$387.62K derived: sum of 2 quarters · filed 2025-05-20 | |||
| 2023-09-30 | $63.47K 10-Q · filed 2025-05-20 | ||||
| 2023-06-30 | $1.04M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |